


PATIENT NAME : SINHA ABHISHEK RANJAN	REF. I	DOCTOR : SELF
	ACCESSION NO : 0002WC05	9628 AGE/SEX : 34 Years Male
	PATIENT ID : SINHM2509	B82 DRAWN :30/03/2023 08:29:23
	CLIENT PATIENT ID:	RECEIVED : 30/03/2023 08:31:23
	ABHA NO :	REPORTED :31/03/2023 13:51:42
Test Report Status <u>Final</u>	Results	i Biological Reference Interval Units
MEDI WHEEL FULL BODY HEALTH CHECK UP BI	ELOW 40 MALE	
XRAY-CHEST		
IMPRESSION	ELEVATED RIGHT DOME OF	DIAPHRAGM ? CAUSE.
TMT OR ECHO		
TMT OR ECHO	NEGATIVE	
ECG		
ECG	WITHIN NORMAL LIMITS	
MEDICAL HISTORY		
RELEVANT PRESENT HISTORY	ALLERGIC RHINITHIS	
RELEVANT PAST HISTORY	COVID 19 INFECTION IN 20	21 AND 2022
RELEVANT PERSONAL HISTORY	ALCOHOL- OCC SMOKING - 5 UNIT/DAY	
RELEVANT FAMILY HISTORY	DIABETES, ASTHMA	
HISTORY OF MEDICATIONS	NOT SIGNIFICANT	
ANTHROPOMETRIC DATA & BMI		
HEIGHT IN METERS	1.65	mts
WEIGHT IN KGS.	83.8	Kgs
BMI	31	BMI & Weight Status as follows/sqmts Below 18.5: Underweight 18.5 - 24.9: Normal 25.0 - 29.9: Overweight 30.0 and Above: Obese
GENERAL EXAMINATION		
MENTAL / EMOTIONAL STATE	NORMAL	
PHYSICAL ATTITUDE	NORMAL	
GENERAL APPEARANCE / NUTRITIONAL STATUS	OBESE	
BUILT / SKELETAL FRAMEWORK	AVERAGE	
FACIAL APPEARANCE	NORMAL	
SKIN	NORMAL	
UPPER LIMB	NORMAL	
LOWER LIMB	NORMAL	
NECK	NORMAL	
NECK LYMPHATICS / SALIVARY GLANDS	NOT ENLARGED OR TENDER	



Dr. J N Shukla ,MBBS, AFIH Consultant Physician









View Details






PATIENT NAME : SINHA ABHISHEK RANJAN	REF. DO	CTOR : SELF
	ACCESSION NO : 0002WC0596	28 AGE/SEX : 34 Years Male
	PATIENT ID : SINHM2509882	DRAWN :30/03/2023 08:29:23
	CLIENT PATIENT ID:	RECEIVED : 30/03/2023 08:31:23
	ABHA NO :	REPORTED :31/03/2023 13:51:42
Test Report Status <u>Final</u>	Results Bio	blogical Reference Interval Units
	NOT ENLARGED	
THYROID GLAND	NORMAL	
CAROTID PULSATION TEMPERATURE	NORMAL	
PULSE		
POLSE	BRUIT	ERAL PULSES WELL FELT, NO CAROTID
RESPIRATORY RATE	NORMAL	
CARDIOVASCULAR SYSTEM		
BP	126/90 MM HG (SUPINE)	mm/Hg
PERICARDIUM	NORMAL	
APEX BEAT	NORMAL	
HEART SOUNDS	S1, S2 HEARD NORMALLY	
MURMURS	ABSENT	
RESPIRATORY SYSTEM		
SIZE AND SHAPE OF CHEST	NORMAL	
MOVEMENTS OF CHEST	SYMMETRICAL	
BREATH SOUNDS INTENSITY	NORMAL	
BREATH SOUNDS QUALITY	VESICULAR (NORMAL)	
ADDED SOUNDS	ABSENT	
PER ABDOMEN		
APPEARANCE	NORMAL	
VENOUS PROMINENCE	ABSENT	
LIVER	NOT PALPABLE	
SPLEEN	NOT PALPABLE	
HERNIA	ABSENT	
CENTRAL NERVOUS SYSTEM		
HIGHER FUNCTIONS	NORMAL	
CRANIAL NERVES	NORMAL	
CEREBELLAR FUNCTIONS	NORMAL	
SENSORY SYSTEM	NORMAL	
MOTOR SYSTEM	NORMAL	
REFLEXES	NORMAL	
MUSCULOSKELETAL SYSTEM		



Dr. J N Shukla ,MBBS, AFIH Consultant Physician



Page 2 Of 21





View Details






PATIENT NAME : SINHA ABHISHEK RANJAN	REF. DOCTOR :	SELF	
	ACCESSION NO : 0002WC059628	AGE/SEX : 34 Years Male	
	PATIENT ID : SINHM2509882	DRAWN :30/03/2023 08:29:23	
	CLIENT PATIENT ID:	RECEIVED : 30/03/2023 08:31:23	
	ABHA NO :	REPORTED :31/03/2023 13:51:42	
Test Report Status <u>Final</u>	Results Biological	Reference Interval Units	
SPINE	NORMAL		
JOINTS	NORMAL		
BASIC EYE EXAMINATION			
CONJUNCTIVA	NORMAL		
EYELIDS	NORMAL		
EYE MOVEMENTS	NORMAL		
CORNEA	NORMAL		
DISTANT VISION RIGHT EYE WITH GLASSES	REDUCE VISUAL ACUITY (6/9)		
DISTANT VISION LEFT EYE WITH GLASSES	WITH GLASSES NORMAL (6/6)		
NEAR VISION RIGHT EYE WITH GLASSES	WITHIN NORMAL LIMIT (N6)		
NEAR VISION LEFT EYE WITH GLASSES	WITHIN NORMAL LIMIT (N6)		
COLOUR VISION	NORMAL (17/17)		
BASIC ENT EXAMINATION			
EXTERNAL EAR CANAL	NORMAL		
TYMPANIC MEMBRANE	NORMAL		
NOSE	NO ABNORMALITY DETECTED		
SINUSES	NORMAL		
THROAT	NO ABNORMALITY DETECTED		
TONSILS	NOT ENLARGED		
BASIC DENTAL EXAMINATION			
TEETH	NORMAL		
GUMS	HEALTHY		
SUMMARY			
RELEVANT HISTORY	NOT SIGNIFICANT		
RELEVANT GP EXAMINATION FINDINGS	NOT SIGNIFICANT		



Dr. J N Shukla ,MBBS, AFIH Consultant Physician



Page 3 Of 21





View Report

View Details





PATIENT NAME : SINHA ABHISHEK RANJAN	REF. DOCTOR	: SELF
	ACCESSION NO : 0002WC059628	AGE/SEX : 34 Years Male
	PATIENT ID : SINHM2509882	DRAWN :30/03/2023 08:29:23
	CLIENT PATIENT ID:	RECEIVED : 30/03/2023 08:31:23
	ABHA NO :	REPORTED :31/03/2023 13:51:42
Test Report Status <u>Final</u>	Results Biologic	al Reference Interval Units
RELEVANT LAB INVESTIGATIONS	RAISED LYMPHOCYTES (44) RAISED FBS (211) RAISED HBA1C (8.7) RAISED EAG (203) RAISED PPBS (357) RAISED TRIGLYCERIDES (369) LOW HDL CHOLESTEROL (32)	

USG-MILD FATTY LIVER

RELEVANT NON PATHOLOGY DIAGNOSTICS REMARKS / RECOMMENDATIONS

RAISED TSH,TRACE GLYCOSURIA,LOW SODIUM,HYPERGLYCEMIA UNCONTROLLED DIABETES WITH ALTERD BLOOD LIPIDS MONITOR TSH REGULARLY FOLLOW UP WITH PHYSICIAN FOR UNCONTROLLED DIABETEC WITH SUBCLINICAL HYPOTHYROIDISM WITH RAISED BLOOD PRESSURE



Dr. J N Shukla ,MBBS, AFIH Consultant Physician



View Details View Report

Page 4 Of 21





PATIENT NAME : SINHA ABHISHEK RANJAN	<b>REF. DOCTOR :</b>	SELF
	ACCESSION NO : 0002WC059628	AGE/SEX : 34 Years Male
	PATIENT ID : SINHM2509882	DRAWN :30/03/2023 08:29:23
	CLIENT PATIENT ID:	RECEIVED : 30/03/2023 08:31:23
	ABHA NO :	REPORTED :31/03/2023 13:51:42
Test Report Status <u>Final</u>	Results	Units

## MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE **ULTRASOUND ABDOMEN**

## **ULTRASOUND ABDOMEN**

-MILD FATTY LIVER.

THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR. THIS IS AN INVIOLABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE. HOWEVER, ALL EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS. 



Dr. J N Shukla , MBBS, AFIH **Consultant Physician** 



Page 5 Of 21

View Report

View Details







**PATIENT NAME : SINHA ABHISHEK RANJAN REF. DOCTOR : SELF** ACCESSION NO : 0002WC059628 AGE/SEX :34 Years Male PATIENT ID : SINHM2509882 DRAWN :30/03/2023 08:29:23 CLIENT PATIENT ID: RECEIVED : 30/03/2023 08:31:23 REPORTED :31/03/2023 13:51:42 ABHA NO : Biological Reference Interval **Test Report Status** <u>Final</u> Results Units

	AEMATOLOGY - CBC		
MEDI WHEEL FULL BODY HEALTH CHECK UP BE	LOW 40 MALE		
BLOOD COUNTS, EDTA WHOLE BLOOD			
HEMOGLOBIN (HB) METHOD : PHOTOMETRIC MEASUREMENT	14.9	13.0 - 17.0	g/dL
RED BLOOD CELL (RBC) COUNT METHOD : COULTER PRINCIPLE	5.07	4.5 - 5.5	mil/µL
WHITE BLOOD CELL (WBC) COUNT METHOD : COULTER PRINCIPLE	7.20	4.0 - 10.0	thou/µL
PLATELET COUNT METHOD : ELECTRONIC IMPEDENCE & MICROSCOPY	168	150 - 410	thou/µL
RBC AND PLATELET INDICES			
HEMATOCRIT (PCV) METHOD : CALCULATED PARAMETER	43.9	40.0 - 50.0	%
MEAN CORPUSCULAR VOLUME (MCV) METHOD : DERIVED PARAMETER FROM RBC HISTOGRAM	86.6	83.0 - 101.0	fL
MEAN CORPUSCULAR HEMOGLOBIN (MCH) METHOD : CALCULATED PARAMETER	29.4	27.0 - 32.0	pg
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD : CALCULATED PARAMETER	33.9	31.5 - 34.5	g/dL
RED CELL DISTRIBUTION WIDTH (RDW) METHOD : DERIVED PARAMETER FROM RBC HISTOGRAM	14.3 High	11.6 - 14.0	%
MENTZER INDEX	17.1		
MEAN PLATELET VOLUME (MPV) METHOD : DERIVED PARAMETER FROM PLATELET HISTOGRAM	11.5 High	6.8 - 10.9	fL
WBC DIFFERENTIAL COUNT			
NEUTROPHILS METHOD : VCSN TECHNOLOGY/ MICROSCOPY	47	40 - 80	%
LYMPHOCYTES METHOD : VCSN TECHNOLOGY/ MICROSCOPY	44 High	20 - 40	%
MONOCYTES METHOD : VCSN TECHNOLOGY/ MICROSCOPY	7	2.0 - 10.0	%
EOSINOPHILS METHOD : VCSN TECHNOLOGY/ MICROSCOPY	1	1.0 - 6.0	%

Dr. Reena Mittal, MD Senior Consultant Hematopathologist



Dr. Sushant Chikane Consultant Pathologist



Ä

View Report

View Details







PATIENT NAME : SINHA ABHISHEK RANJAN	REF. DOCTOR	: SELF
	ACCESSION NO : 0002WC059628	AGE/SEX : 34 Years Male
	PATIENT ID : SINHM2509882	DRAWN :30/03/2023 08:29:23
	CLIENT PATIENT ID:	RECEIVED : 30/03/2023 08:31:23
	ABHA NO :	REPORTED :31/03/2023 13:51:42
Test Report Status Final	Results Biologia	al Reference Interval Units

Test Report Status Final	Results	Biological Reference	Interval Units
BASOPHILS METHOD : VCSN TECHNOLOGY/ MICROSCOPY	1	0 - 1	%
ABSOLUTE NEUTROPHIL COUNT METHOD : CALCULATED PARAMETER	3.40	2.0 - 7.0	thou/µL
ABSOLUTE LYMPHOCYTE COUNT METHOD : CALCULATED PARAMETER	3.17 High	1.0 - 3.0	thou/µL
ABSOLUTE MONOCYTE COUNT METHOD : CALCULATED PARAMETER	0.50	0.2 - 1.0	thou/µL
ABSOLUTE EOSINOPHIL COUNT METHOD : CALCULATED PARAMETER	0.07	0.02 - 0.50	thou/µL
ABSOLUTE BASOPHIL COUNT METHOD : CALCULATED PARAMETER	0.07	0.02 - 0.10	thou/µL
NEUTROPHIL LYMPHOCYTE RATIO (NLR) METHOD : CALCULATED	1.1		

Interpretation(s) BLOOD COUNTS,EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology. RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.</li>
 WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive.

patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients ; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.

Dr. Reena Mittal, MD Senior Consultant Hematopathologist

**Dr. Sushant Chikane Consultant Pathologist** 





Page 7 Of 21

View Details







PATIENT NAME : SINHA ABHISHEK RANJAN **REF. DOCTOR : SELF** ACCESSION NO : 0002WC059628 AGE/SEX :34 Years Male :30/03/2023 08:29:23 PATIENT ID : SINHM2509882 DRAWN CLIENT PATIENT ID: RECEIVED : 30/03/2023 08:31:23 ABHA NO REPORTED :31/03/2023 13:51:42 : Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

MEDI WHEEL FULL BODY HE	ALTH CHECK UP BELOW 40 MALE		
ERYTHROCYTE SEDIMENTAT BLOOD	ION RATE (ESR),WHOLE		
		0 - 14	mm at 1 hr

#### Interpretation(s)

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION :-

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

## **TEST INTERPRETATION**

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis). In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum. Decreased in: Polycythermia vera, Sickle cell anemia

### LIMITATIONS

False elevated ESR : Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia False Decreased : Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine, salicylates)

**REFERENCE** :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th edition.

Dr. Reena Mittal, MD Senior Consultant Hematopathologist



**Dr. Sushant Chikane Consultant Pathologist** 



View Report

Page 8 Of 21

Details







**PATIENT NAME : SINHA ABHISHEK RANJAN REF. DOCTOR : SELF** ACCESSION NO : 0002WC059628 AGE/SEX :34 Years Male PATIENT ID DRAWN :30/03/2023 08:29:23 : SINHM2509882 CLIENT PATIENT ID: RECEIVED : 30/03/2023 08:31:23 ABHA NO REPORTED :31/03/2023 13:51:42 : **Test Report Status** Results **Biological Reference Interval** Units <u>Final</u>

	IMMUNOHAEMATOLOGY
MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE	
ABO GROUP & RH TYPE, EDTA WHOLE BL	OOD
ABO GROUP METHOD : HAEMAGGLUTINATION (AUTOMATED)	В
RH TYPE METHOD : HAEMAGGLUTINATION (AUTOMATED)	POSITIVE

Interpretation(s) ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same.

The test is performed by both forward as well as reverse grouping methods.

**Dr. Sushant Chikane Consultant Pathologist** 



Page 9 Of 21

View Report







PATIENT NAME : SINHA ABHISHEK RANJAN **REF. DOCTOR : SELF** ACCESSION NO : 0002WC059628 AGE/SEX :34 Years Male :30/03/2023 08:29:23 PATIENT ID : SINHM2509882 DRAWN CLIENT PATIENT ID: RECEIVED : 30/03/2023 08:31:23 ABHA NO REPORTED :31/03/2023 13:51:42 : **Test Report Status** Results **Biological Reference Interval** Units **Final** 

BIOCHEMISTRY MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE **GLUCOSE FASTING, FLUORIDE PLASMA** 211 High mg/dL FBS (FASTING BLOOD SUGAR) Normal <100 Impaired fasting glucose:100 to 125 Diabetes mellitus: > = 126 (on more than 1 occassion) (ADA guidelines 2021) METHOD : SPECTROPHOTOMETRY HEXOKINASE **GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE** BLOOD 8.7 High Non-diabetic Adult < 5.7 % HBA1C Pre-diabetes 5.7 - 6.4 Diabetes diagnosis: > or = 6.5Therapeutic goals: < 7.0Action suggested : > 8.0(ADA Guideline 2021) METHOD : ION- EXCHANGE HPLC 203.0 High ESTIMATED AVERAGE GLUCOSE(EAG) < 116 mg/dL **GLUCOSE, POST-PRANDIAL, PLASMA** PPBS(POST PRANDIAL BLOOD SUGAR) 357 High Normal <140 mg/dL Impaired glucose tolerance:140 to 199 Diabetes mellitus : > = 200 (on more than 1 occassion) ADA guideline 2021 METHOD : SPECTROPHOTOMETRY HEXOKINASE LIPID PROFILE, SERUM Desirable : < 200 158 mg/dL CHOLESTEROL, TOTAL Borderline : 200 - 239 High : > / = 240METHOD : SPECTROPHOTOMETRY, ENZYMATIC COLORIMETRIC - CHOLETSEROL OXIDASE, ESTERASE, PEROXIDASE TRIGLYCERIDES 369 High Normal: < 150 mg/dL Borderline high: 150 - 199 High: 200 - 499 Very High: >/= 500

METHOD : SPECTROPHOTOMETRY, ENZYMATIC ENDPOINT WITH GLYCEROL BLANK

Dr. Sneha Wadalkar, M.D (Reg.no.MMC2012/06/1868) Junior Biochemist











**PATIENT NAME : SINHA ABHISHEK RANJAN REF. DOCTOR : SELF** ACCESSION NO : 0002WC059628 AGE/SEX :34 Years Male PATIENT ID DRAWN :30/03/2023 08:29:23 : SINHM2509882 CLIENT PATIENT ID: RECEIVED : 30/03/2023 08:31:23 ABHA NO REPORTED :31/03/2023 13:51:42 :

Test Report Status <u>Final</u>	Results	Biological Reference Interval Units
	32 Low	
HDL CHOLESTEROL		At Risk: < 40 mg/dL Desirable: > or = 60
METHOD : SPECTROPHOTOMETRY, HOMOGENEOUS DIRE	CT ENZYMATIC COLORIMETRIC	
CHOLESTEROL LDL	52	Optimal : < 100 mg/dL Near optimal/above optimal : 100-129 Borderline high : 130-159 High : 160-189 Very high : = 190
METHOD : CALCULATED PARAMETER		
NON HDL CHOLESTEROL	126	Desirable : < 130 mg/dL Above Desirable : 130 -159 Borderline High : 160 - 189 High : 190 - 219 Very high : > / = 220
	74 0 High	cor 20.0 mg/dl
VERY LOW DENSITY LIPOPROTEIN METHOD : CALCULATED PARAMETER	74.0 High	< or = 30.0 mg/dL
CHOL/HDL RATIO	4.9 High	Low Risk : 3.3 - 4.4 Average Risk : 4.5 - 7.0 Moderate Risk : 7.1 - 11.0 High Risk : > 11.0
METHOD : CALCULATED PARAMETER		
LDL/HDL RATIO	2.7	Desirable/Low Risk : 0.5 - 3.0 Borderline/Moderate Risk : 3.1 - 6.0 High Risk : > 6.0

METHOD : CALCULATED PARAMETER


## Interpretation(s)

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India		
Risk Category		
Extreme risk group	A.CAD with $> 1$ feature of high risk group	
	B. CAD with > 1 feature of Very high risk group or recurrent ACS (within 1 year) despite LDL-C < or =	
	50 mg/dl or polyvascular disease	
Very High Risk	1. Established ASCVD 2. Diabetes with 2 major risk factors or evidence of end organ damage 3.	
	Familial Homozygous Hypercholesterolemia	

8. wadal

Dr. Sneha Wadalkar, M.D (Reg.no.MMC2012/06/1868) Junior Biochemist



Page 11 Of 21



Details







	INHA ABHI	SHEK RANJAN			<b>REF. DOCTOR :</b>			
			ACCESSI	ION NO : <b>0002</b>	WC059628	AGE/SEX	:34 Years	Male
		PATIENT ID : SINHM2509882		DRAWN	DRAWN :30/03/2023 08:29:23			
			CLIENT P	ATIENT ID:		RECEIVED	: 30/03/202	3 08:31:23
			ABHA NC			i	:31/03/202	
							51,00,202	
est Report Status	<u>Final</u>	i	Resu	lts	Biological	Reference	e Interval	Units
High Risk		ajor ASCVD risk factor						
		CKD stage 3B or 4. 4. ium - CAC >300 AU.						
Moderate Risk		CVD risk factors			0			-
Low Risk	0-1 major A	ASCVD risk factors						
		cardiovascular disease)						
		d > or = 55 years in fem	ales	3. Current Ci	garette smoking or t	obacco use		
2. Family history of pr	remature ASC	CVD		4. High blood	l pressure			
5. Low HDL								
	and statin in	nitiation thresholds bas	sed on th	ne risk categori				_
Risk Group		Treatment Goals			Consider Drug T			
		LDL-C (mg/dl)		IDL (mg/dl)	LDL-C (mg/dl)		L (mg/dl)	
Extreme Risk Group C		<50 (Optional goal < OR = 30 )	< OR =		>OR = 50	>OR = 80		
Extreme Risk Group C	Category B	<or 30<="" =="" td=""><td><or =<="" td=""><td>= 60</td><td>&gt; 30</td><td>&gt;60</td><td></td><td>_</td></or></td></or>	<or =<="" td=""><td>= 60</td><td>&gt; 30</td><td>&gt;60</td><td></td><td>_</td></or>	= 60	> 30	>60		_
Very High Risk		<50	<80		>OR= 50	>OR= 80		
High Risk		<70	<100		>OR= 70	>OR=100		
Moderate Risk		<100	<130		>OR=100	>OR=130		
Low Risk		<100	<130		>OR=130*	>OR=160		
References: Managemen ndia. Current Vascular	nt of Dyslipid Pharmacolog							ciation of
References: Managemen ndia. Current Vascular IVER FUNCTION PI	nt of Dyslipid Pharmacolog	daemia for the Preventio gy, 2022, 20, 134-155. <b>RUM</b>					ne Lipid Asso	 ociation of ng/dL
References: Managemen ndia. Current Vascular	nt of Dyslipid Pharmacolog ROFILE, SE	daemia for the Preventio gy, 2022, 20, 134-155. RUM	on of Stro		actice Recommenda		ne Lipid Asso	
References: Managemer ndia. Current Vascular IVER FUNCTION PI ILIRUBIN, TOTAL METHOD : SPECTROPHOTO	nt of Dyslipid Pharmacolog ROFILE, SE	daemia for the Preventio gy, 2022, 20, 134-155. ERUM METRIC -DIAZO METHOD	on of Stro 0.43		actice Recommenda Upto 1.2	tions from th	ne Lipid Asso n	ng/dL
References: Managemer ndia. Current Vascular IVER FUNCTION PI ULIRUBIN, TOTAL METHOD : SPECTROPHOTO ILIRUBIN, DIRECT	nt of Dyslipid Pharmacolog <b>ROFILE, SE</b> METRY, COLORII	daemia for the Preventio y, 2022, 20, 134-155. <b>RUM</b> METRIC -DIAZO METHOD	on of Stro 0.43 0.19		actice Recommenda	tions from th	ne Lipid Asso n	
References: Managemer ndia. Current Vascular IVER FUNCTION PI ULIRUBIN, TOTAL METHOD : SPECTROPHOTO ILIRUBIN, DIRECT	nt of Dyslipid Pharmacolog ROFILE, SE METRY, COLORIN METRY, JENDRA	daemia for the Preventio gy, 2022, 20, 134-155. ERUM METRIC -DIAZO METHOD ASSIK & GROFF - DIAZOTIZA	on of Stro 0.43 0.19		actice Recommenda Upto 1.2	tions from th	ne Lipid Asso n n	ng/dL
References: Managemer ndia. Current Vascular IVER FUNCTION PI BILIRUBIN, TOTAL METHOD : SPECTROPHOTO BILIRUBIN, DIRECT METHOD : SPECTROPHOTO	nt of Dyslipid Pharmacolog ROFILE, SE METRY, COLORIN METRY, JENDRA: CCT	daemia for the Preventio gy, 2022, 20, 134-155. ERUM METRIC -DIAZO METHOD ASSIK & GROFF - DIAZOTIZA	0.43 0.19		actice Recommenda Upto 1.2 < or = 0.1	tions from th	ne Lipid Asso n n	ng/dL ng/dL
References: Managemer IVER FUNCTION PI SILIRUBIN, TOTAL METHOD : SPECTROPHOTOD SILIRUBIN, DIRECT METHOD : SPECTROPHOTOD SILIRUBIN, INDIRE METHOD : CALCULATED PA OTAL PROTEIN	nt of Dyslipid Pharmacolog ROFILE, SE METRY, COLORIN METRY, JENDRA CT ARAMETER	daemia for the Preventio gy, 2022, 20, 134-155. ERUM METRIC -DIAZO METHOD ASSIK & GROFF - DIAZOTIZA	0.43 0.19 0.24 7.3	oke: Clinical Pr	actice Recommenda Upto 1.2 < or = 0.1	tions from th	ne Lipid Asso n n n	ng/dL ng/dL
References: Managemen india. Current Vascular IVER FUNCTION PI BILIRUBIN, TOTAL METHOD : SPECTROPHOTOD BILIRUBIN, DIRECT METHOD : SPECTROPHOTOD BILIRUBIN, INDIRE METHOD : CALCULATED PA OTAL PROTEIN METHOD : SPECTROPHOTOD	nt of Dyslipid Pharmacolog ROFILE, SE METRY, COLORIN METRY, JENDRA CT ARAMETER	daemia for the Preventio gy, 2022, 20, 134-155. ERUM METRIC -DIAZO METHOD ASSIK & GROFF - DIAZOTIZA METRIC -BIURET, REAGENT	0.43 0.19 0.24 7.3 BLANK, SE	oke: Clinical Pr	actice Recommenda Upto 1.2 < or = 0. 0.0 - 0.9 6.0 - 8.0	utions from th	ne Lipid Asso n n g	ng/dL ng/dL ng/dL /dL
References: Managemen india. Current Vascular IVER FUNCTION PI BILIRUBIN, TOTAL METHOD : SPECTROPHOTO BILIRUBIN, DIRECT METHOD : SPECTROPHOTO BILIRUBIN, INDIRE METHOD : CALCULATED PA OTAL PROTEIN METHOD : SPECTROPHOTO LBUMIN	nt of Dyslipid Pharmacolog ROFILE, SE METRY, COLORIN METRY, JENDRA: CCT ARAMETER METRY, COLORIN	daemia for the Preventio gy, 2022, 20, 134-155. ERUM METRIC -DIAZO METHOD ASSIK & GROFF - DIAZOTIZA METRIC -BIURET, REAGENT	0.43 0.19 0.24 7.3 BLANK, SE 4.5	oke: Clinical Pr	actice Recommenda Upto 1.2 < or = 0.1 0.0 - 0.9	utions from th	ne Lipid Asso n n g	ng/dL ng/dL ng/dL
References: Managemen dia. Current Vascular IVER FUNCTION PI BILIRUBIN, TOTAL METHOD : SPECTROPHOTOD BILIRUBIN, DIRECT METHOD : SPECTROPHOTOD BILIRUBIN, INDIRE METHOD : CALCULATED PA OTAL PROTEIN METHOD : SPECTROPHOTOD LBUMIN METHOD : SPECTROPHOTOD SLOBULIN	Int of Dyslipid Pharmacolog ROFILE, SE DMETRY, COLORIA C DMETRY, JENDRA CCT ARAMETER DMETRY, COLORIA DMETRY, BROMOO	daemia for the Preventio gy, 2022, 20, 134-155. ERUM METRIC -DIAZO METHOD ASSIK & GROFF - DIAZOTIZA METRIC -BIURET, REAGENT	0.43 0.19 0.24 7.3 BLANK, SE 4.5	oke: Clinical Pr	actice Recommenda Upto 1.2 < or = 0. 0.0 - 0.9 6.0 - 8.0	utions from th	he Lipid Asso n n g g	ng/dL ng/dL ng/dL /dL
References: Managemen india. Current Vascular IVER FUNCTION PI ILIRUBIN, TOTAL METHOD : SPECTROPHOTO ILIRUBIN, DIRECT METHOD : SPECTROPHOTO ILIRUBIN, INDIRE METHOD : CALCULATED PA LBUMIN METHOD : SPECTROPHOTO ILBUMIN METHOD : CALCULATED PA LBUMIN/GLOBULI	Int of Dyslipid Pharmacolog ROFILE, SE METRY, COLORIN C METRY, JENDRA: CCT ARAMETER METRY, COLORIN METRY, BROMOO ARAMETER N RATIO	daemia for the Preventio gy, 2022, 20, 134-155. ERUM METRIC -DIAZO METHOD ASSIK & GROFF - DIAZOTIZA METRIC -BIURET, REAGENT	0.43 0.19 0.24 7.3 BLANK, SE 4.5 BINDING	oke: Clinical Pr	actice Recommenda Upto 1.2 < or = 0.1 0.0 - 0.9 6.0 - 8.0 3.97 - 4.9	utions from th	he Lipid Asso n n g g g	ng/dL ng/dL ng/dL /dL /dL
References: Managemen dia. Current Vascular IVER FUNCTION PI BILIRUBIN, TOTAL METHOD : SPECTROPHOTO BILIRUBIN, DIRECT METHOD : SPECTROPHOTO BILIRUBIN, INDIRE METHOD : CALCULATED PA COTAL PROTEIN METHOD : SPECTROPHOTO GLOBULIN METHOD : CALCULATED PA LBUMIN/GLOBULII METHOD : CALCULATED PA	Int of Dyslipid Pharmacolog ROFILE, SE METRY, COLORIA METRY, JENDRA CCT ARAMETER METRY, COLORIA METRY, BROMOG ARAMETER N RATIO ARAMETER	daemia for the Prevention (y, 2022, 20, 134-155. ERUM METRIC -DIAZO METHOD ASSIK & GROFF - DIAZOTIZA METRIC -BIURET, REAGENT CRESOL GREEN(BCG) - DYE	0.43 0.19 0.24 7.3 BLANK, SE 4.5 BINDING 2.8 1.6	oke: Clinical Pr	actice Recommenda Upto 1.2 < or = 0.1 0.0 - 0.9 6.0 - 8.0 3.97 - 4.9 2.0 - 3.5 1.0 - 2.1	utions from th	he Lipid Asso n n g g g R	ng/dL ng/dL /dL /dL /dL ATIO
References: Managemen dia. Current Vascular IVER FUNCTION PI BILIRUBIN, TOTAL METHOD : SPECTROPHOTO BILIRUBIN, DIRECT METHOD : SPECTROPHOTO BILIRUBIN, INDIRE METHOD : CALCULATED PA OTAL PROTEIN METHOD : SPECTROPHOTO GLOBULIN METHOD : CALCULATED PA ALBUMIN/GLOBULII METHOD : CALCULATED PA SPARTATE AMINO AST/SGOT)	Int of Dyslipid Pharmacolog ROFILE, SE METRY, COLORIA DIMETRY, JENDRAS ECT ARAMETER DIMETRY, COLORIA DIMETRY, BROMOC ARAMETER N RATIO ARAMETER DTRANSFER/	daemia for the Prevention (y, 2022, 20, 134-155. ERUM METRIC -DIAZO METHOD ASSIK & GROFF - DIAZOTIZA METRIC -BIURET, REAGENT CRESOL GREEN(BCG) - DYE	0.43 0.19 0.24 7.3 BLANK, SE 4.5 BINDING 2.8 1.6 <b>71 Hig</b>	oke: Clinical Pr erum blank	actice Recommenda Upto 1.2 < or = 0.1 0.0 - 0.9 6.0 - 8.0 3.97 - 4.9 2.0 - 3.5	utions from th	he Lipid Asso n n g g g R	ng/dL ng/dL /dL /dL /dL
References: Managemen Maia. Current Vascular IVER FUNCTION PI BILIRUBIN, TOTAL METHOD : SPECTROPHOTOD BILIRUBIN, DIRECT METHOD : SPECTROPHOTOD BILIRUBIN, INDIRE METHOD : CALCULATED PA OTAL PROTEIN METHOD : SPECTROPHOTOD SLOBULIN METHOD : CALCULATED PA ALBUMIN/GLOBULII METHOD : CALCULATED PA ALBUMIN/GLOBULII METHOD : CALCULATED PA ASPARTATE AMINO AST/SGOT) METHOD : SPECTROPHOTOD	Int of Dyslipid Pharmacolog ROFILE, SE METRY, COLORIA DIMETRY, JENDRAS ECT ARAMETER DIMETRY, COLORIA DIMETRY, BROMOC ARAMETER N RATIO ARAMETER DTRANSFER/	daemia for the Prevention (y, 2022, 20, 134-155. ERUM METRIC -DIAZO METHOD ASSIK & GROFF - DIAZOTIZA METRIC -BIURET, REAGENT CRESOL GREEN(BCG) - DYE ASE	0.43 0.19 0.24 7.3 BLANK, SE 4.5 BINDING 2.8 1.6 <b>71 Hig</b>	oke: Clinical Pr erum blank	actice Recommenda Upto 1.2 < or = 0.1 0.0 - 0.9 6.0 - 8.0 3.97 - 4.9 2.0 - 3.5 1.0 - 2.1	utions from th	he Lipid Asso n n g g g R	ng/dL ng/dL /dL /dL /dL ATIO
References: Managemen Maia. Current Vascular IVER FUNCTION PI BILIRUBIN, TOTAL METHOD : SPECTROPHOTOD BILIRUBIN, DIRECT METHOD : SPECTROPHOTOD BILIRUBIN, INDIRE METHOD : CALCULATED PA OTAL PROTEIN METHOD : SPECTROPHOTOD SLOBULIN METHOD : CALCULATED PA ALBUMIN/GLOBULII METHOD : CALCULATED PA ALBUMIN/GLOBULII METHOD : CALCULATED PA ASPARTATE AMINO AST/SGOT) METHOD : SPECTROPHOTOD	Int of Dyslipid Pharmacolog ROFILE, SE METRY, COLORIA DIMETRY, JENDRAS ECT ARAMETER DIMETRY, COLORIA DIMETRY, BROMOC ARAMETER N RATIO ARAMETER DTRANSFER/	daemia for the Prevention (y, 2022, 20, 134-155. ERUM METRIC -DIAZO METHOD ASSIK & GROFF - DIAZOTIZA METRIC -BIURET, REAGENT CRESOL GREEN(BCG) - DYE ASE	0.43 0.19 0.24 7.3 BLANK, SE 4.5 BINDING 2.8 1.6 <b>71 Hig</b>	oke: Clinical Pr erum blank	actice Recommenda Upto 1.2 < or = 0.1 0.0 - 0.9 6.0 - 8.0 3.97 - 4.9 2.0 - 3.5 1.0 - 2.1	utions from th	he Lipid Asso n n g g g R	ng/dL ng/dL /dL /dL /dL ATIO //L
References: Managemen dia. Current Vascular IVER FUNCTION PI BILIRUBIN, TOTAL METHOD : SPECTROPHOTO BILIRUBIN, DIRECT METHOD : SPECTROPHOTO BILIRUBIN, INDIRE METHOD : CALCULATED PA OTAL PROTEIN METHOD : SPECTROPHOTO GLOBULIN METHOD : CALCULATED PA ALBUMIN/GLOBULII METHOD : CALCULATED PA SPARTATE AMINO AST/SGOT)	Int of Dyslipid Pharmacolog ROFILE, SE METRY, COLORIA C METRY, JENDRAS CCT ARAMETER METRY, COLORIA METRY, BROMOC ARAMETER N RATIO ARAMETER DTRANSFER/ METRY, WITHOU	daemia for the Prevention (y, 2022, 20, 134-155. ERUM METRIC -DIAZO METHOD ASSIK & GROFF - DIAZOTIZA METRIC -BIURET, REAGENT CRESOL GREEN(BCG) - DYE ASE	0.43 0.19 0.24 7.3 BLANK, SE 4.5 BINDING 2.8 1.6 <b>71 Hig</b>	oke: Clinical Pr erum blank	actice Recommenda Upto 1.2 < or = 0.1 0.0 - 0.9 6.0 - 8.0 3.97 - 4.9 2.0 - 3.5 1.0 - 2.1	utions from th	he Lipid Asso n n g g g R	ng/dL ng/dL /dL /dL /dL ATIO //L
References: Managemen dia. Current Vascular IVER FUNCTION PI BILIRUBIN, TOTAL METHOD : SPECTROPHOTO BILIRUBIN, DIRECT METHOD : SPECTROPHOTO BILIRUBIN, INDIRE METHOD : CALCULATED PA OTAL PROTEIN METHOD : SPECTROPHOTO LBUMIN METHOD : SPECTROPHOTO BLOBULIN METHOD : CALCULATED PA LBUMIN/GLOBULII METHOD : CALCULATED PA SPARTATE AMINO AST/SGOT) METHOD : SPECTROPHOTO METHOD : SPECTROPHOTO SPARTATE AMINO AST/SGOT) METHOD : SPECTROPHOTO METHOD : SPECTROPHOTO SPARTATE AMINO AST/SGOT) METHOD : SPECTROPHOTO METHOD : SPECTROPHOTO SOLULIAN METHOD : SPECTROPHOTO METHOD : CALCULATED PA SPARTATE AMINO METHOD : SPECTROPHOTO METHOD : SPECTROPH	Int of Dyslipid Pharmacolog ROFILE, SE METRY, COLORIA C METRY, JENDRAS CCT ARAMETER METRY, COLORIA METRY, BROMOC ARAMETER N RATIO ARAMETER DTRANSFER/ METRY, WITHOU	daemia for the Prevention (y, 2022, 20, 134-155. ERUM METRIC -DIAZO METHOD ASSIK & GROFF - DIAZOTIZA METRIC -BIURET, REAGENT CRESOL GREEN(BCG) - DYE ASE	0.43 0.19 0.24 7.3 BLANK, SE 4.5 BINDING 2.8 1.6 <b>71 Hig</b>	oke: Clinical Pr erum blank	actice Recommenda Upto 1.2 < or = 0.1 0.0 - 0.9 6.0 - 8.0 3.97 - 4.9 2.0 - 3.5 1.0 - 2.1	utions from th	he Lipid Asso n n g g g R	ng/dL ng/dL /dL /dL /dL ATTO //L Page 12 Of 21







PATIENT NAME : SINHA ABHISHEK RANJAN **REF. DOCTOR : SELF** ACCESSION NO : 0002WC059628 AGE/SEX :34 Years Male :30/03/2023 08:29:23 PATIENT ID : SINHM2509882 DRAWN CLIENT PATIENT ID: RECEIVED : 30/03/2023 08:31:23 ABHA NO REPORTED :31/03/2023 13:51:42 : Biological Reference Interval Test Report Status Results Units **Final** U/L 97 High ALANINE AMINOTRANSFERASE (ALT/SGPT) Upto 41 METHOD : SPECTROPHOTOMETRY, WITHOUT PYRIDOXAL PHOSPHATE ACTIVATION( P5P) - IFCC ALKALINE PHOSPHATASE 132 High 40 - 129 U/L METHOD : SPECTROPHOTOMETRY, PNPP, AMP BUFFER - IFCC GAMMA GLUTAMYL TRANSFERASE (GGT) 92 High < 60 U/L METHOD : SPECTROPHOTOMETRY, ENZYMATIC COLORIMETRIC - G-GLUTAMYL-CARBOXY-NITROANILIDE - IFCC < 232 U/L LACTATE DEHYDROGENASE 196 METHOD : SPECTROPHOTOMETRY, LACTATE TO PYRUVATE - UV-IFCC **BLOOD UREA NITROGEN (BUN), SERUM BLOOD UREA NITROGEN** 11 6 - 20 mg/dL METHOD : SPECTROPHOTOMETRY, UREASE -COLORIMETRIC **CREATININE, SERUM** CREATININE 0.96 0.90 - 1.30mg/dL METHOD : SPECTROPHOTOMETRY, JAFFE'S ALKALINE PICRATE KINETIC - RATE BLANKED - IFCC-IDMS STANDARIZED **BUN/CREAT RATIO BUN/CREAT RATIO** 8 - 15 11.46 METHOD : CALCULATED PARAMETER URIC ACID, SERUM 5.6 3.4 - 7.0 mg/dL URIC ACID METHOD : SPECTROPHOTOMETRY, ENZYMATIC COLORIMETRIC- URICASE **TOTAL PROTEIN, SERUM** TOTAL PROTEIN 7.3 6.0 - 8.0 g/dL METHOD : SPECTROPHOTOMETRY, COLORIMETRIC -BIURET, REAGENT BLANK, SERUM BLANK ALBUMIN, SERUM ALBUMIN 4.5 3.97 - 4.94 g/dL METHOD : SPECTROPHOTOMETRY, BROMOCRESOL GREEN(BCG) - DYE BINDING GLOBULIN GLOBULIN 2.8 2.0 - 3.5 g/dL METHOD : CALCULATED PARAMETER **ELECTROLYTES (NA/K/CL), SERUM** 134 Low mmol/L SODIUM, SERUM 136 - 145 METHOD : ISE INDIRECT POTASSIUM, SERUM 4.90 3.5 - 5.1mmol/L METHOD : ISE INDIRECT CHLORIDE, SERUM 100 98 - 106 mmol/L

8. wada

Dr. Sneha Wadalkar,M.D (Reg.no.MMC2012/06/1868) Junior Biochemist Page 13 Of 21



view Details







PATIENT NAME : SINHA ABHISHEK RANJAN **REF. DOCTOR : SELF** ACCESSION NO : 0002WC059628 AGE/SEX :34 Years Male :30/03/2023 08:29:23 PATIENT ID : SINHM2509882 DRAWN CLIENT PATIENT ID: RECEIVED : 30/03/2023 08:31:23 ABHA NO REPORTED :31/03/2023 13:51:42 : Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

### METHOD : ISE INDIRECT

### Interpretation(s)

Sodium	Potassium	Chloride
Decreased in:CCF, cirrhosis, vomiting, diarrhea, excessive sweating, salt-losing nephropathy, adrenal insufficiency, nephrotic syndrome, water intoxication, SIADH. Drugs: thiazides, diuretics, ACE inhibitors, chlorpropamide, carbamazepine, anti depressants (SSRI), antipsychotics.	Decreased in: Low potassium intake,prolonged vomiting or diarrhea, RTA types I and II, hyperaldosteronism, Cushing's syndrome,osmotic diuresis (e.g., hyperglycemia),alkalosis, familial periodic paralysis,trauma (transient).Drugs: Adrenergic agents, diuretics.	Decreased in: Vomiting, diarrhea, renal failure combined with salt deprivation, over-treatment with diuretics, chronic respiratory acidosis, diabetic ketoacidosis, excessive sweating, SIADH, salt-losing nephropathy, porphyria, expansion of extracellular fluid volume, adrenalinsufficiency, hyperaldosteronism, metabolic alkalosis. Drugs: chronic laxative,corticosteroids, diuretics.
Increased in: Dehydration (excessivesweating, severe vomiting or diarrhea),diabetes mellitus, diabetesinsipidus, hyperaldosteronism, inadequate water intake. Drugs: steroids, licorice,oral contraceptives.	Increased in: Massive hemolysis, severe tissue damage, rhabdomyolysis, acidosis, dehydration,renal failure, Addison' s disease, RTA type IV, hyperkalemic familial periodic paralysis. Drugs: potassium salts, potassium- sparing diuretics,NSAIDs, beta-blockers, ACE inhibitors, high- dose trimethoprim-sulfamethoxazole.	Increased in: Renal failure, nephrotic syndrome, RTA, dehydration, overtreatment with saline, hyperparathyroidism, diabetes insipidus, metabolic acidosis from diarrhea (Loss of HCO3-), respiratory alkalosis, hyperadrenocorticism. Drugs: acetazolamide, androgens, hydrochlorothiazide, salicylates.
Interferences: Severe lipemia or hyperproteinemi, if sodium analysis involves a dilution step can cause spurious results. The serum sodium falls about 1.6 mEq/L for each 100 mg/dL increase in blood glucose.	Interferences: Hemolysis of sample, delayed separation of serum, prolonged fist clenching during blood drawing, and prolonged tourniquet placement. Very high WBC/PLT counts may cause spurious. Plasma potassium levels are normal.	Interferences:Test is helpful in assessing normal and increased anion gap metabolic acidosis and in distinguishing hypercalcemia due to hyperparathyroidism (high serum chloride) from that due to malignancy (Normal serum chloride)

#### Interpretation(s)

GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the urine.

Increased in: Diabetes mellitus, Cushing's syndrome (10 - 15%), chronic pancreatitis (30%). Drugs: corticosteroids, phenytoin, estrogen, thiazides.

Decreased in :Pancreatic islet cell disease with increased insulin,insulinoma, adrenocortical insufficiency, hypopituitarism, diffuse liver disease, malignancy(adrenocortical, stomach, fibrosarcoma), infant of a diabetic mother, enzyme deficiency

diseases(e.g.galactosemia), Drugs-insulin, ethanol, propranolol; sulfonylureas, tolbutamide, and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin (HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-Used For:

1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.

- Diagnosing diabetes.
  Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range. 1. eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.

a. A G gives an evaluation of blood glucose levels for the last couple of months.
 a. AG is calculated as eAG (mg/dl) = 28.7 \* HbA1c - 46.7

8. wadal

SRL Ltd

Mumbai, 400062

Dr. Sneha Wadalkar, M.D (Reg.no.MMC2012/06/1868) Junior Biochemist



Page 14 Of 21





View Report

Details







PATIENT NAME : SINHA ABHISHEK RANJAN	REF. DOCTOR : SELF			
	ACCESSION NO : 0002WC	AGE/SEX : 34 Years Male		
	PATIENT ID : SINHM25	DRAWN :30/03/2023 08:29:23		
	CLIENT PATIENT ID:	RECEIVED : 30/03/2023 08:31:23		
	ABHA NO :	REPORTED :31/03/2023 13:51:42		
Test Report Status <u>Final</u>	Results	Biological Reference Interval Units		

### HbA1c Estimation can get affected due to :

1. Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.

2.Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin. 3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results. 4. Interference of hemoglobinopathies in HbA1c estimation is seen in

a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)

c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, (undirect) bilirubin in Viral hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elsevated more than unconjugated (indirect) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Galstones getting into the bile ducts, tumors & Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood.ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease. GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain

and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc.

Total Protein also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease.Lower-than-normal levels may be due to: Agammaglobulinemia,Bleeding (hemorrhage),Burns,Glomerulonephritis,Liver disease, Malabsorption,Malnutrition,Nephrotic syndrome, Protein-losing enteropathy etc.

Albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc

BLODD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism) Causes of decreased level include Liver disease, SIADH.

CREATININE, SERUM-Higher than normal level may be due to: • Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia) Lower than normal level may be due to:

## Myasthenia Gravis, Muscuophy

URIC ACID, SERUM-Causes of Increased levels-Dietary(High Protein Intake,Prolonged Fasting,Rapid weight loss),Gout,Lesch nyhan syndrome,Type 2 DM,Metabolic syndrome Causes of decreased levels-Low Zinc intake,OCP,Multiple Sclerosis

TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum.Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma,Waldenstroms disease

Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc. ALBUMIN, SERUM-

Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance,malnutrition and wasting etc.

S.S. Wadal

Dr. Sneha Wadalkar, M.D (Reg.no.MMC2012/06/1868) Junior Biochemist



Page 15 Of 21

/iew Details







**PATIENT NAME : SINHA ABHISHEK RANJAN REF. DOCTOR : SELF** ACCESSION NO : 0002WC059628 AGE/SEX :34 Years Male :30/03/2023 08:29:23 PATIENT ID : SINHM2509882 DRAWN CLIENT PATIENT ID: RECEIVED : 30/03/2023 08:31:23 ABHA NO REPORTED :31/03/2023 13:51:42 : Test Report Status **Final** Results Biological Reference Interval Units

~				
CLINIC	AL PATH - URINALYSIS			
MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE				
PHYSICAL EXAMINATION, URINE				
COLOR	PALE YELLOW			
APPEARANCE	CLEAR			
CHEMICAL EXAMINATION, URINE				
PH	6.0	5.00 - 7.50		
SPECIFIC GRAVITY	1.005 Low	1.010 - 1.030		
PROTEIN	NOT DETECTED	NOT DETECTED		
GLUCOSE	DETECTED (TRACE)	NOT DETECTED		
KETONES	NOT DETECTED	NOT DETECTED		
BLOOD	NOT DETECTED	NOT DETECTED		
BILIRUBIN	NOT DETECTED	NOT DETECTED		
UROBILINOGEN	NOT DETECTED			
NITRITE	NOT DETECTED	NOT DETECTED		
LEUKOCYTE ESTERASE	NOT DETECTED	NOT DETECTED		
MICROSCOPIC EXAMINATION, URINE				
RED BLOOD CELLS	NOT DETECTED	NOT DETECTED	/HPF	
PUS CELL (WBC'S)	0-1	0-5	/HPF	
EPITHELIAL CELLS	0-1	0-5	/HPF	
CASTS	NOT DETECTED			
CRYSTALS	NOT DETECTED			
BACTERIA	NOT DETECTED	NOT DETECTED		
YEAST	NOT DETECTED	NOT DETECTED		
METHOD : URINE ROUTINE & MICROSCOPY EXAMINATION BY INTEG	RATED AUTOMATED SYSTEM			

## Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions
Proteins	Inflammation or immune illnesses
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind of kidney impairment

S.S. Wadal

Dr. Sneha Wadalkar, M.D (Reg.no.MMC2012/06/1868) Junior Biochemist

Page 16 Of 21



Details







**PATIENT NAME : SINHA ABHISHEK RANJAN REF. DOCTOR : SELF** ACCESSION NO : 0002WC059628 AGE/SEX :34 Years Male PATIENT ID : SINHM2509882 DRAWN :30/03/2023 08:29:23 CLIENT PATIENT ID: RECEIVED : 30/03/2023 08:31:23 REPORTED :31/03/2023 13:51:42 ABHA NO :


Test Report Status Final Results	Biological Refere

Units ence Interval

Glucose	Diabetes or kidney disease	
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst	
Urobilinogen	Liver disease such as hepatitis or cirrhosis	
Blood	Renal or genital disorders/trauma	
Bilirubin	Liver disease	
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary tract infection and glomerular diseases	
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either acute or chronic, polycystic kidney disease, urolithiasis, contamination by genital secretions	
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or bladder catheters for prolonged periods of time	
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration, interaction with Bence-Jones protein	
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal diseases	
Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit (Averrhoa carambola) or its juice	
Uric acid	arthritis	
Bacteria	Urinary infectionwhen present in significant numbers & with pus cells.	
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis	

g.g.wadal

Dr. Sneha Wadalkar, M.D (Reg.no.MMC2012/06/1868) Junior Biochemist



Page 17 Of 21



Details View







**PATIENT NAME : SINHA ABHISHEK RANJAN REF. DOCTOR : SELF** ACCESSION NO : 0002WC059628 AGE/SEX :34 Years Male PATIENT ID DRAWN :30/03/2023 08:29:23 : SINHM2509882 CLIENT PATIENT ID: RECEIVED : 30/03/2023 08:31:23 ABHA NO REPORTED :31/03/2023 13:51:42 : **Test Report Status** Results Biological Reference Interval Units <u>Final</u>

## **CLINICAL PATH - STOOL ANALYSIS**

# MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

MICROSCOPIC EXAMINATION, STOOL

## TEST CANCELLED AS SPECIMEN NOT RECEIVED

## Interpretation(s)

REMARK

Stool routine analysis is only a screening test for disorders of gastrointentestinal tract like infection, malabsorption, etc. The following table describes the probable conditions, in which the analytes are present in stool.

PRESENCE OF	CONDITION
Pus cells	Pus in the stool is an indication of infection
Red Blood cells	Parasitic or bacterial infection or an inflammatory bowel condition such as ulcerative colitis
Parasites	Infection of the digestive system. Stool examination for ova and parasite detects presence of parasitic infestation of gastrointestinal tract. Various forms of parasite that can be detected include cyst, trophozoite and larvae. One negative result does not rule out the possibility of parasitic infestation. Intermittent shedding of parasites warrants examinations of multiple specimens tested on consecutive days. Stool specimens for parasitic examination should be collected before initiation of antidiarrheal therapy or antiparasitic therapy. This test does not detect presence of opportunistic parasites like Cyclospora, Cryptosporidia and Isospora species. Examination of Ova and Parasite has been carried out by direct and concentration techniques.
Mucus	Mucus is a protective layer that lubricates, protects& reduces damage due to bacteria or viruses.
Charcot-Leyden crystal	Parasitic diseases.
Ova & cyst	Ova & cyst indicate parasitic infestation of intestine.
Frank blood	Bleeding in the rectum or colon.
Occult blood	Occult blood indicates upper GI bleeding.
Macrophages	Macrophages in stool are an indication of infection as they are protective cells.
Epithelial cells	Epithelial cells that normally line the body surface and internal organs show up in stool when there is inflammation or infection.
Fat	Increased fat in stool maybe seen in conditions like diarrhoea or malabsorption.
рН	Normal stool pH is slightly acidic to neutral. Breast-fed babies generally have an acidic stool.

## ADDITIONAL STOOL TESTS :

- <u>Stool Culture</u>:- This test is done to find cause of GI infection, make decision about best treatment for GI infection & to find out if treatment for GI infection worked.
- 2. <u>Fecal Calprotectin</u>: It is a marker of intestinal inflammation. This test is done to differentiate Inflammatory Bowel Disease (IBD) from Irritable Bowel Syndrome (IBS).

Dr. Ekta Patil,MD (Reg.No. MMC2008/04/1142) Senior Microbiologist



Page 18 Of 21

Vie<u>w Report</u>

View Details








MC-2010

PATIENT NAME : SINHA ABHISHEK RANJAN	REF. DOCTOR :	SELF
	ACCESSION NO : 0002WC059628	AGE/SEX : 34 Years Male
	PATIENT ID : SINHM2509882	DRAWN :30/03/2023 08:29:23
	CLIENT PATIENT ID:	RECEIVED : 30/03/2023 08:31:23
	ABHA NO :	REPORTED :31/03/2023 13:51:42
		<u> </u>
Test Report Status <u>Final</u>	Results Biological	Reference Interval Units

- - 3. Fecal Occult Blood Test(FOBT): This test is done to screen for colon cancer & to evaluate possible cause of unexplained anaemia. 4. Clostridium Difficile Toxin Assay: This test is strongly recommended in healthcare associated bloody or waterydiarrhoea, due to overuse of broad spectrum antibiotics which alter the normal GI flora.
  - Biofire (Film Array) GI PANEL: In patients of Diarrhoea, Dysentry, Rice watery Stool, FDA approved, Biofire Film Array 5. Test,(Real Time Multiplex PCR) is strongly recommended as it identifies organisms, bacteria, fungi, virus , parasite and other opportunistic pathogens, Vibrio cholera infections only in 3 hours. Sensitivity 96% & Specificity 99%.
  - Rota Virus Immunoassay: This test is recommended in severe gastroenteritis in infants & children associated with watery 6. diarrhoea, vomitting& abdominal cramps. Adults are also affected. It is highly contagious in nature.



Dr. Ekta Patil, MD (Reg.No. MMC2008/04/1142) Senior Microbiologist



Page 19 Of 21





Vie<u>w</u> Details







PATIENT NAME : SINHA ABHISHEK RANJAN	REF. DOCTOR	: SELF
	ACCESSION NO : 0002WC059628	AGE/SEX : 34 Years Male
	PATIENT ID : SINHM2509882	DRAWN :30/03/2023 08:29:23
	CLIENT PATIENT ID:	RECEIVED : 30/03/2023 08:31:23
	ABHA NO :	REPORTED :31/03/2023 13:51:42
Test Report Status <u>Final</u>	Results Biologic	al Reference Interval Units

# SPECIALISED CHEMISTRY - HORMONE

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE				
THYROID PANEL, SERUM				
ТЗ	154.0	80.0 - 200.0	ng/dL	
METHOD : COMPETITIVE ELECTROCHEMILUMINESCENCE IMMUNC	DASSAY			
T4	10.80	5.10 - 14.10	µg/dL	
METHOD : COMPETITIVE ELECTROCHEMILUMINESCENCE IMMUNC	DASSAY			
TSH (ULTRASENSITIVE)	8.590 High	0.270 - 4.200	µIU/mL	
METHOD : SANDWICH ELECTROCHEMILUMINESCENCE IMMUNOA	SSAY			

## Interpretation(s)

Triiodothyronine T3, Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3. Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, Free T4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3)
					Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid
	4.202				hormone replacement therapy (3) In cases of Autoimmune/Hashimoto
					thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical
					inflammation, drugs like amphetamines, Iodine containing drug and
					dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre
					(3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid
					hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4
					replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism
6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent
					treatment for Hyperthyroidism

S.S. Wadal

Dr. Sneha Wadalkar, M.D (Reg.no.MMC2012/06/1868) Junior Biochemist



Page 20 Of 21

/iew Details







**PATIENT NAME : SINHA ABHISHEK RANJAN REF. DOCTOR : SELF** ACCESSION NO : 0002WC059628 AGE/SEX :34 Years Male PATIENT ID DRAWN :30/03/2023 08:29:23 : SINHM2509882 CLIENT PATIENT ID: RECEIVED : 30/03/2023 08:31:23 ABHA NO REPORTED :31/03/2023 13:51:42 : **Test Report Status** Results **Biological Reference Interval** Units <u>Final</u>

8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness			
9	Low	High	High	0	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies			
REF: 1. 7	EF: 1. TIETZ Fundamentals of Clinical chemistry 2. Guidlines of the American Thyroid association duriing pregnancy and Postpartum, 2011.							

NOTE: It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

> \*\*End Of Report\*\* Please visit www.srlworld.com for related Test Information for this accession

CONDITIONS OF LABORATORY TESTING & REPORTING					
1. It is presumed that the test sample belongs to the patient	5. SRL confirms that all tests have been performed or				
named or identified in the test requisition form.	assayed with highest quality standards, clinical safety &				
2. All tests are performed and reported as per the	technical integrity.				
turnaround time stated in the SRL Directory of Services.	6. Laboratory results should not be interpreted in isolation;				
3. Result delays could occur due to unforeseen	it must be correlated with clinical information and be				
circumstances such as non-availability of kits / equipment	interpreted by registered medical practitioners only to				
breakdown / natural calamities / technical downtime or any	determine final diagnosis.				
other unforeseen event.	<ol><li>Test results may vary based on time of collection,</li></ol>				
4. A requested test might not be performed if:	physiological condition of the patient, current medication or				
i. Specimen received is insufficient or inappropriate	nutritional and dietary changes. Please consult your doctor				
ii. Specimen quality is unsatisfactory	or call us for any clarification.				
iii. Incorrect specimen type	8. Test results cannot be used for Medico legal purposes.				
iv. Discrepancy between identification on specimen	9. In case of queries please call customer care				
container label and test requisition form	(91115 91115) within 48 hours of the report.				
	SRL Limited				
	Fortis Hospital, Sector 62, Phase VIII, Mohali 160062				
	Mohali 160062				

S.S. Wadal

Dr. Sneha Wadalkar, M.D (Reg.no.MMC2012/06/1868) Junior Biochemist



Page 21 Of 21

